Can crash dieting affect blood-cell production, and does it have implications for blood cancer? Oncologist explains

The Hidden Risks of Extreme Caloric Restriction

In the pursuit of rapid weight loss, many individuals turn to crash dieting, a practice characterized by severe caloric restriction and the elimination of entire food groups. While weight loss is often viewed through the lens of aesthetics or general fitness, the biological reality is far more complex. Dr. Liza Bulsara, a haematologist and paediatric oncologist at MOC Cancer Care, Pune, highlights that when dieting shifts from mindful, controlled caloric deficits to extreme deprivation, it compromises the body's fundamental physiological processes, specifically hematopoiesis—the production of blood cells.

The Mechanics of Hematopoietic Failure

The bone marrow requires a constant supply of essential micronutrients, including iron, vitamin B12, folate, and specific proteins, to synthesize new red and white blood cells and platelets. When a crash diet strips the body of these building blocks, the bone marrow cannot maintain adequate production rates. This leads to conditions such as anemia, characterized by fatigue and reduced oxygen transport, and leukopenia, which leaves the immune system vulnerable to infections. Chronic nutritional stress essentially starves the body's "blood factory," creating a fragile internal environment.

The Link to Malignancy and Blood Cancer

Perhaps the most concerning implication raised by Dr. Bulsara is the potential long-term connection between severe, recurring nutritional deficiency and the development of blood cancers. While a single episode of dieting is unlikely to cause cancer, chronic systemic stress and the impairment of cellular repair mechanisms can create an environment where genetic mutations are more likely to persist and propagate. By hindering the body's ability to produce healthy, functional blood cells, extreme dieting may inadvertently weaken the surveillance mechanisms that typically detect and eliminate early-stage malignant cells.